Pharmaceutical thrombosis prevention in cardiovascular disease

Expert Opinion on Investigational Drugs
Mats ErikssonAnders Larsson

Abstract

Cardiovascular diseases are a leading cause of morbidity and mortality in modern society. As a result of this, great efforts have been made to establish regimens for prophylaxis and treatment of such disorders. Pharmacological intervention is also a prerequisite for the success of other therapeutic approaches, e.g. coronary angioplasty. Prevention of platelet aggregation is a goal that can be achieved by counteracting various receptors on the platelet surface. The main attentions for such interventions are focused on inhibiting the glycoprotein IIb/IIIa receptor. So far, they are limited to intravenous usage. Adenosine diphosphate receptor inhibitors are available for intravenous and oral usage. Their effect is, at least partly, also exerted via the counteraction of adenosine diphosphate-mediated activation of the glycoprotein IIb/IIIa complex. An oral direct thrombin inhibitor is under clinical evaluation. This review focuses on atherothrombotic disorders, but recent advances within new fields of anticoagulation (i.e., treatment of severe septic shock and a novel approach to prevent thromboembolic disorder during surgery) should not be overlooked.

References

Feb 1, 1997·Proceedings of the Society for Experimental Biology and Medicine·L T Kim, K M Yamada
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
Aug 15, 1998·The New England Journal of Medicine·UNKNOWN Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigato
Dec 5, 1998·Toxicon : Official Journal of the International Society on Toxinology·F S Markland
Jan 8, 1999·Drugs·K J McClellan, K L Goa
Apr 3, 1999·Drugs·M Dooley, K L Goa
Apr 3, 1999·Medicinal Research Reviews·P E Sanderson
Mar 23, 2000·Toxicon : Official Journal of the International Society on Toxinology·K ZhaoZ Lin
Sep 12, 2000·Current Cardiology Reports·S R Hankins, E M Horn
Nov 4, 2000·Expert Opinion on Investigational Drugs·M ErikssonA Nordgren
Jan 6, 2001·Lancet·UNKNOWN ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Apr 27, 2001·Expert Opinion on Investigational Drugs·T SteinmetzerJ Sturzebecher
May 1, 2001·Biochemical and Biophysical Research Communications·P SaviJ M Herbert
Jun 15, 2001·Journal of Thrombosis and Thrombolysis·G Proimos
Jun 23, 2001·The New England Journal of Medicine·E J TopolUNKNOWN TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Current Atherosclerosis Reports
Girish R Mood, Deepak L Bhatt
Drugs of Today
Athanasios I PapathanasiouAlexandros D Tselepis
Current Atherosclerosis Reports
Girish R MoodDeepak L Bhatt
© 2022 Meta ULC. All rights reserved